Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
NCT ID: NCT02957656
Last Updated: 2018-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
53 participants
INTERVENTIONAL
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine
NCT03581903
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
NCT02921997
H7N9 Boost in Healthy Adults
NCT02586792
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
NCT01995695
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
NCT01942265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will enroll healthy adults who will choose which study group to join. Participants in Group 1 will receive one dose of H7N9 pLAIV in an inpatient setting at study entry (Day 0). They will remain in an isolation unit through at least Day 9. They will also receive one dose of AS03-adjuvanted H7N9 pIIV on Day 84.
Participants in Group 2 will receive one dose of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and a second dose of AS03-adjuvanted H7N9 pIIV at Day 84. Participants in Group 3 will receive one dose of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
All participants will attend multiple study visits through Day 264. Study visits may include blood collection, physical examinations, and nasal wash and nasal wick procedures.
These three groups will be compared to two historical control groups who received one dose of H7N9 pLAIV at study entry (Day 0), one dose of H7N9 pLAIV at Day 28, and one dose of unadjuvanted H7N9 pIIV at Day 84.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV
Participants will receive one dose of approximately 10\^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
H7N9 pLAIV
10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
H7N9 pIIV
Administered by intramuscular injection in the deltoid.
AS03 adjuvant
Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV
Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
H7N9 pIIV
Administered by intramuscular injection in the deltoid.
AS03 adjuvant
Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
Group 3: AS03-adjuvanted H7N9 pIIV
Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
H7N9 pIIV
Administered by intramuscular injection in the deltoid.
AS03 adjuvant
Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
University of Rochester URMC 13-001 Participants
Participants received one dose of 10\^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10\^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
H7N9 pLAIV
10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
H7N9 pIIV
Administered by intramuscular injection in the deltoid.
Johns Hopkins School of Public Health CIR293 Participants
Participants received one dose of 10\^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10\^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
H7N9 pLAIV
10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
H7N9 pIIV
Administered by intramuscular injection in the deltoid.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
H7N9 pLAIV
10\^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
H7N9 pIIV
Administered by intramuscular injection in the deltoid.
AS03 adjuvant
Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are in good health, as determined by medical history and targeted physical examination to ensure any existing medical diagnoses or conditions (except those exclusionary) are stable. More information on this criterion can be found in the protocol.
* Agree to storage of blood specimens for future research.
* Available for the duration of the trial. Subjects must be willing and able to remain within the Isolation Unit for the specified duration of confinement.
* Provide written informed consent prior to initiation of any study procedures, including future use of specimens.
* Female subjects of childbearing potential must agree to use effective birth control methods for the duration of the study (for example, pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; intrauterine device; abstinence from heterosexual intercourse, surgical sterilization). All female subjects will be considered being of childbearing potential except those who have undergone hysterectomy or tubal ligation and those in whom menopause occurred at least 1 year prior to the study.
* Agrees not to participate in another clinical trial with an investigational product for the entire duration of the study.
* Oral temperature is less than 100.4°F.
* Pulse is 50 to 115 bpm, inclusive.
* Systolic blood pressure is 85 to 150 mm Hg, inclusive.
* Diastolic blood pressure is 55 to 95 mm Hg, inclusive.
* Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to study vaccination.
Exclusion Criteria
* Currently breastfeeding or planning to breastfeed at some point during the duration of the study.
* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, electrocardiogram (EKG) and/or laboratory studies including urine testing. Alanine aminotransferase (ALT) levels greater than 2 times the upper normal limit will be exclusionary at baseline, prior to vaccination.
* Any current illness requiring daily medication other than the following: vitamins, birth control, anti-hypertensive medication, antihistamines, anti-depressant medication, cholesterol-lowering medication, treatment for gastroesophageal reflux disease, and thyroid medication unless approved by the PI.
* Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol.
* Previous enrollment in an H7 or H9 influenza vaccine trial or in any study of an avian influenza vaccine.
* Seropositive to the H7N9 influenza A virus (serum HAI titer greater than 1:8).
* Positive urine drug toxicology test indicating narcotic use/dependency.
* Have medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.
* Have a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines.
* Have known hypersensitivity or allergy to eggs, egg or chicken protein, squalene-based adjuvants, or other components of the study vaccine.
* Allergy to oseltamivir as determined by subject report.
* Current diagnosis of asthma or reactive airway disease (within the past 2 years).
* History of Guillain-Barré Syndrome.
* Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory Western blot tests for human immunodeficiency virus-1 (HIV-1).
* Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for hepatitis C virus (HCV).
* Positive hepatitis B virus surface antigen (HBsAg) by ELISA.
* Known immunodeficiency syndrome.
* Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to vaccination.
* Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study vaccination.
* Planned receipt of any vaccine from the first study vaccination through the follow-up visit at approximately 180 days after the final study vaccination.
* History of asplenia.
* Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 36 months prior to vaccination.
* Have known active neoplastic disease or a history of any hematologic malignancy.
* Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination.
* Current smoker unwilling to stop smoking for the duration of the inpatient stay.
* A current smoker includes anyone stating they currently smoke or use any amount of a tobacco product, including electronic cigarettes.
* After admission to the unit, nicotine patches will be provided to current smokers who request them for the inpatient portion of the study.
* Travel to the Southern Hemisphere within 14 days prior to study vaccination.
* Travel on a cruise ship within 14 days prior to study vaccination.
* Receipt of another investigational vaccine or drug within 30 days prior to study vaccination.
* Any potential Immune Mediated Disease (pIMD) listed in the protocol, or other diseases that may have an autoimmune origin.
20 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angela Branche
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rochester Medical Center
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.